B.E. Sands
Mount Sinai Hospital
63 Papers
8 Citations
B.E. Sands is an academic researcher from Mount Sinai Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Efficacy and Safety of Mirikizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Study.
Geert R. D'Haens,T. Kobayashi,Nathan Morris,Trevor Lissoos,Amy Hoover,X. Li,V Arora,Catherine Milch,W J Sandborn,B.E. Sands +9 more
TL;DR: In this phase 3 UC study, 300mg miri IV demonstrated statistically significant and clinically meaningful improvements vs PBO in all primary and key secondary endpoints across clinical, endoscopic, histologic, and symptomatic measures, with an acceptable safety profile.
OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study
B.E. Sands,BG Feagan,W J Sandborn,N. Shipitofsky,M Marko,Shihong Sheng,Jewel Johanns,Matthew Germinaro,M. Vetter,Julián Panés +9 more
TL;DR: Combination induction treatment with GUS+GOL more effectively induced clinical response, clinical remission, and endoscopic improvement at wk12 than either monotherapy alone.
36
OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results
B.E. Sands,Laurent Peyrin-Biroulet,Silvio Danese,D. Rubin,Saar Vermeire,O. Laurent,Allison Luo,D. Nguyen,Anna Wiechowska-Kozłowska,Jaroslaw Leszczyszyn,Radosław Kempiński,Jaroslaw Kierkus,Timothy E. Ritter,BG Feagan,Stephan R. Targan +14 more
TL;DR: In this paper , PRA023 is an anti-TL1A monoclonal antibody in development for multiple inflammatory/fibrotic diseases using a precision medicine approach with a companion diagnostic (CDx).
OP24 Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: Week 48 analyses from the phase 2 GALAXI 1 study
Silvio Danese,Remo Panaccione,D. Rubin,B.E. Sands,Walter Reinisch,Geert R. D'Haens,Julián Panés,S. González,Kathleen M. Weisel,A. Sahoo,Mary Ellen Frustaci,Z. Yang,W J Sandborn,Anita Afzali,Tadanori Hisamatsu,Jane M. Andrews,BG Feagan +16 more
TL;DR: GUS induction followed by SC maintenance achieved high rates of clinical efficacy at Wk48 and key safety event rates were similar among GUS dose groups (Table 3); no opportunistic infections, cases of tuberculosis, or deaths were reported in any group.
17
P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study
B.E. Sands,Stephen B. Hanauer,Jean-Frederic Colombel,W J Sandborn,Stefan Schreiber,Silvio Danese,Maria Kłopocka,R. L. Kulynych,Jaroslaw Kierkus,A. Soltysiak,P. Smolinski,Maciej Gonciarz,S. Sreckovic,E. Yu. Valuyskikh,Marek Horynski,Adriano Gasbarrini,S. H. Kim,Yunju Bae,S J Lee,J.-H. Lee,J. G. Lee,S. G. Lee,J. M. Kim +22 more
TL;DR: In this article , CT-P13 subcutaneous (SC) infliximab formulation was developed to provide patients with a convenient option for treatment of ulcerative colitis.
15